1298Associations of DMT therapies with COVID-19 severity in multiple sclerosis
Steve Simpson(University of Tasmania), Liesbet M. Peeters(Hasselt University), Tim Spelman(Peter Doherty Institute), Edward De Brouwer(KU Leuven), Richard Nicholas(Swansea University), Nick Rijke(Multiple Sclerosis International Federation), Lotte Geyes(University of Technology Sydney), Ricardo Alonso(Hospital Ramos Mejía), Maria Fernandes Mendes(University of Technology Sydney), Amber Salter(Salter School), Tomáš Kalinčík(The Royal Melbourne Hospital), Helmut Butzkueven(Monash Alfred Psychiatry Research centre), Lars A. Forsberg(University of Technology Sydney), Anneke van der Walt(The Alfred Hospital), Gıancarlo Comı(Vita-Salute San Raffaele University), Clare Walton(Multiple Sclerosis International Federation), Alexander Stahmann(Unknown), R Ivanov, Amin Ardeshirdavani(KU Leuven), Aníbal Chertcoff(Hospital Británico de Buenos Aires), Robert McBurney(Accelerated Cure Project for Multiple Sclerosis), Nikola Lazovski, Jan Hillert, Ana Zabalza(Universitat Autònoma de Barcelona), Ashkan Pirmani(Hasselt University), Alice Estavo Dias(Brazilian Medical Association), Ingrid van der Mei(University of Tasmania), Alexander Fidao(The University of Melbourne), Tina Parciak(Universitätsmedizin Göttingen), Doralina Guimarães Brum(National Cancer Center), Robert Fox(University of Technology Sydney), Georgina Arrambide(Universitat Autònoma de Barcelona), Rojas Juan(University of Technology Sydney), Nupur Nag(Mental Health Research Institute), Clément Gautrais(KU Leuven), Guilherme Sciascia do Olival(Brazilian Medical Association), Johana Bauer, Hollie Schmidt(Research Network (United States)), Stefan Braune, Anna Glaser(Karolinska Institutet), Arnfin Bergmann, Rod Middleton(Swansea University), Gilles Edan, Melinda Magyari(University of Copenhagen)
Cited by 7
Related Papers
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Multiple Sclerosis Severity Score
|Neurology|2005|957